Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Accounts Payables (2020 - 2026)

Rani Therapeutics Holdings' Accounts Payables history spans 7 years, with the latest figure at $858000.0 for Q1 2026.

  • On a quarterly basis, Accounts Payables fell 43.55% to $858000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $858000.0, a 43.55% decrease, with the full-year FY2025 number at $309000.0, down 77.26% from a year prior.
  • Accounts Payables came in at $858000.0 for Q1 2026, up from $309000.0 in the prior quarter.
  • The five-year high for Accounts Payables was $2.5 million in Q3 2025, with the low at $309000.0 in Q4 2025.
  • Historically, Accounts Payables has averaged $1.3 million across 5 years, with a median of $1.4 million in 2023.
  • Peak annual rise in Accounts Payables hit 255.34% in 2025, while the deepest fall reached 77.26% in 2025.
  • Year by year, Accounts Payables stood at $1.5 million in 2022, then tumbled by 55.62% to $648000.0 in 2023, then soared by 109.72% to $1.4 million in 2024, then crashed by 77.26% to $309000.0 in 2025, then soared by 177.67% to $858000.0 in 2026.
  • Business Quant data shows Accounts Payables for RANI at $858000.0 in Q1 2026, $309000.0 in Q4 2025, and $2.5 million in Q3 2025.